1. Home
  2. QNTM vs MDAI Comparison

QNTM vs MDAI Comparison

Compare QNTM & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QNTM
  • MDAI
  • Stock Information
  • Founded
  • QNTM 1998
  • MDAI 2013
  • Country
  • QNTM Canada
  • MDAI United States
  • Employees
  • QNTM N/A
  • MDAI N/A
  • Industry
  • QNTM
  • MDAI Medical/Dental Instruments
  • Sector
  • QNTM
  • MDAI Health Care
  • Exchange
  • QNTM NYSE
  • MDAI Nasdaq
  • Market Cap
  • QNTM 69.3M
  • MDAI 69.0M
  • IPO Year
  • QNTM N/A
  • MDAI N/A
  • Fundamental
  • Price
  • QNTM $25.15
  • MDAI $2.60
  • Analyst Decision
  • QNTM
  • MDAI Strong Buy
  • Analyst Count
  • QNTM 0
  • MDAI 2
  • Target Price
  • QNTM N/A
  • MDAI $4.75
  • AVG Volume (30 Days)
  • QNTM 188.7K
  • MDAI 787.8K
  • Earning Date
  • QNTM 08-13-2025
  • MDAI 08-11-2025
  • Dividend Yield
  • QNTM N/A
  • MDAI N/A
  • EPS Growth
  • QNTM N/A
  • MDAI N/A
  • EPS
  • QNTM N/A
  • MDAI N/A
  • Revenue
  • QNTM N/A
  • MDAI $29,962,000.00
  • Revenue This Year
  • QNTM N/A
  • MDAI N/A
  • Revenue Next Year
  • QNTM N/A
  • MDAI $15.15
  • P/E Ratio
  • QNTM N/A
  • MDAI N/A
  • Revenue Growth
  • QNTM N/A
  • MDAI 55.21
  • 52 Week Low
  • QNTM $2.70
  • MDAI $0.82
  • 52 Week High
  • QNTM $38.25
  • MDAI $3.25
  • Technical
  • Relative Strength Index (RSI)
  • QNTM 61.07
  • MDAI 54.14
  • Support Level
  • QNTM $21.63
  • MDAI $2.43
  • Resistance Level
  • QNTM $24.61
  • MDAI $2.75
  • Average True Range (ATR)
  • QNTM 2.37
  • MDAI 0.21
  • MACD
  • QNTM 0.27
  • MDAI -0.06
  • Stochastic Oscillator
  • QNTM 91.60
  • MDAI 29.07

About QNTM QUANTUM BIOPHARMA LTD

Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.

About MDAI Spectral AI Inc.

Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.

Share on Social Networks: